Bản sửa đổi năm 2016 đối với phân loại các bệnh u của Tổ chức Y tế Thế giới về các khối u tủy và bạch cầu cấp tính

Jabbour, 2014, Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management., Am J Hematol, 89, 547, 10.1002/ajh.23691

O’Brien, 2014, Chronic myelogenous leukemia, version 1.2015., J Natl Compr Canc Netw, 12, 1590, 10.6004/jnccn.2014.0159

Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013., Blood, 122, 872, 10.1182/blood-2013-05-501569

Hehlmann, 2015, CML--Where do we stand in 2015?, Ann Hematol, 94, S103, 10.1007/s00277-015-2331-1

Deininger, 2015, Diagnosing and managing advanced chronic myeloid leukemia., Am Soc Clin Oncol Educ Book, 35, e381, 10.14694/EdBook_AM.2015.35.e381

Barbui, 2015, Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis., Blood Cancer J, 5, e337, 10.1038/bcj.2015.64

Tefferi, 2014, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis., Blood, 124, 2507, 10.1182/blood-2014-05-579136

Tefferi, 2014, An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms., Leukemia, 28, 1407, 10.1038/leu.2014.35

Maxson, 2013, Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML., N Engl J Med, 368, 1781, 10.1056/NEJMoa1214514

Barbui, 2014, Masked polycythemia vera (mPV): results of an international study., Am J Hematol, 89, 52, 10.1002/ajh.23585

Barbui, 2016, Myeloproliferative neoplasms: Morphology and clinical practice., Am J Hematol, 91, 430, 10.1002/ajh.24288

Thiele, 2011, Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification., Blood, 117, 5710, 10.1182/blood-2010-07-293761

Barbui, 2011, Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study., J Clin Oncol, 29, 3179, 10.1200/JCO.2010.34.5298

Gisslinger, Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria [published online ahead of print December 29, 2015]., Leukemia

Barosi, 2012, Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis., PLoS One, 7, e35631, 10.1371/journal.pone.0035631

Madelung, 2013, World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience., Am J Hematol, 88, 1012, 10.1002/ajh.23554

Gisslinger, 2013, Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial., Blood, 121, 1720, 10.1182/blood-2012-07-443770

Gianelli, 2014, Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms., Mod Pathol, 27, 814, 10.1038/modpathol.2013.196

Valent, 2015, Diagnosis and management of mastocytosis: an emerging challenge in applied hematology., Hematology (Am Soc Hematol Educ Program), 2015, 98, 10.1182/asheducation-2015.1.98

Valent, 2001, Diagnostic criteria and classification of mastocytosis: a consensus proposal., Leuk Res, 25, 603, 10.1016/S0145-2126(01)00038-8

Patterer, 2013, Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1., Ann Hematol, 92, 759, 10.1007/s00277-013-1695-3

Bain, 2014, Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?, Br J Haematol, 166, 809, 10.1111/bjh.12963

Rumi, 2015, Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene., Ann Hematol, 94, 1927, 10.1007/s00277-015-2451-7

Orazi, 2008, The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features., Leukemia, 22, 1308, 10.1038/leu.2008.119

Locatelli, 2015, How I treat juvenile myelomonocytic leukemia., Blood, 125, 1083, 10.1182/blood-2014-08-550483

Mughal, 2015, An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms., Haematologica, 100, 1117, 10.3324/haematol.2014.114660

Itzykson, 2013, Prognostic score including gene mutations in chronic myelomonocytic leukemia., J Clin Oncol, 31, 2428, 10.1200/JCO.2012.47.3314

Meggendorfer, 2013, SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations., Leukemia, 27, 1852, 10.1038/leu.2013.133

Patnaik, 2016, Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia., Blood Cancer J, 6, e393, 10.1038/bcj.2016.5

Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes., N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617

Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence., N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405

Ricci, 2010, RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant., Clin Cancer Res, 16, 2246, 10.1158/1078-0432.CCR-09-2112

Schuler, 2014, Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias., Leuk Res, 38, 1413, 10.1016/j.leukres.2014.09.003

Cervera, 2014, Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia., Am J Hematol, 89, 604, 10.1002/ajh.23702

Storniolo, 1990, Chronic myelomonocytic leukemia., Leukemia, 4, 766

Boiocchi, 2013, Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease., Mod Pathol, 26, 204, 10.1038/modpathol.2012.165

Boiocchi, 2015, Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications., Mod Pathol, 28, 1448, 10.1038/modpathol.2015.100

Wang, 2014, Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms., Blood, 123, 2645, 10.1182/blood-2014-02-553800

Piazza, 2013, Recurrent SETBP1 mutations in atypical chronic myeloid leukemia., Nat Genet, 45, 18, 10.1038/ng.2495

Gambacorti-Passerini, 2015, Recurrent ETNK1 mutations in atypical chronic myeloid leukemia., Blood, 125, 499, 10.1182/blood-2014-06-579466

Malcovati, 2011, Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms., Blood, 118, 6239, 10.1182/blood-2011-09-377275

Papaemmanuil, 2011, Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts., N Engl J Med, 365, 1384, 10.1056/NEJMoa1103283

Bejar, 2012, Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes., J Clin Oncol, 30, 3376, 10.1200/JCO.2011.40.7379

Cazzola, 2013, Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms., Blood, 121, 260, 10.1182/blood-2012-09-399725

Passmore, 1995, Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system., Blood, 85, 1742, 10.1182/blood.V85.7.1742.bloodjournal8571742

Niemeyer, 1997, Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases., Blood, 89, 3534

Verburgh, 2007, A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification., Leukemia, 21, 668, 10.1038/sj.leu.2404564

Germing, 2012, Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes., Leuk Res, 36, 727, 10.1016/j.leukres.2012.02.014

Maassen, 2013, Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts., Leuk Res, 37, 64, 10.1016/j.leukres.2012.09.021

Senent, 2013, Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes., Haematologica, 98, 568, 10.3324/haematol.2012.071449

Font, 2013, Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification., Ann Hematol, 92, 19, 10.1007/s00277-012-1565-4

Parmentier, 2012, Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors., Haematologica, 97, 723, 10.3324/haematol.2011.056879

Della Porta, 2015, Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes., Leukemia, 29, 66, 10.1038/leu.2014.161

Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes., Blood, 120, 2454, 10.1182/blood-2012-03-420489

Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262

Germing, 2012, Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study., Leukemia, 26, 1286, 10.1038/leu.2011.391

Mallo, 2011, Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q., Leukemia, 25, 110, 10.1038/leu.2010.231

Schanz, 2012, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge., J Clin Oncol, 30, 820, 10.1200/JCO.2011.35.6394

Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes., Blood, 122, 3616, 10.1182/blood-2013-08-518886

Haferlach, 2014, Landscape of genetic lesions in 944 patients with myelodysplastic syndromes., Leukemia, 28, 241, 10.1038/leu.2013.336

Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes., Blood, 126, 9, 10.1182/blood-2015-03-631747

Kwok, 2015, MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance., Blood, 126, 2355, 10.1182/blood-2015-08-667063

Cargo, 2015, Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression., Blood, 126, 2362, 10.1182/blood-2015-08-663237

Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes., N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343

Bejar, 2014, Clinical and genetic predictors of prognosis in myelodysplastic syndromes., Haematologica, 99, 956, 10.3324/haematol.2013.085217

Bejar, 2014, Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation., J Clin Oncol, 32, 2691, 10.1200/JCO.2013.52.3381

Mallo, 2013, Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations., Br J Haematol, 162, 74, 10.1111/bjh.12354

Saft, 2014, p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)., Haematologica, 99, 1041, 10.3324/haematol.2013.098103

Jädersten, 2011, TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression., J Clin Oncol, 29, 1971, 10.1200/JCO.2010.31.8576

del Rey, 2015, Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts., PLoS One, 10, e0126555, 10.1371/journal.pone.0126555

Gerstung, 2015, Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes., Nat Commun, 6, 5901, 10.1038/ncomms6901

Malcovati, 2015, SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts., Blood, 126, 233, 10.1182/blood-2015-03-633537

Patnaik, 2012, Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts., Blood, 119, 5674, 10.1182/blood-2012-03-415356

West, 2014, Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations., Ann N Y Acad Sci, 1310, 111, 10.1111/nyas.12346

Grimwade, 2010, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials., Blood, 116, 354, 10.1182/blood-2009-11-254441

Gröschel, 2014, A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia., Cell, 157, 369, 10.1016/j.cell.2014.02.019

Yamazaki, 2014, A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression., Cancer Cell, 25, 415, 10.1016/j.ccr.2014.02.008

Soupir, 2007, Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis., Am J Clin Pathol, 127, 642, 10.1309/B4NVER1AJJ84CTUU

Konoplev, 2013, Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia., Leuk Lymphoma, 54, 138, 10.3109/10428194.2012.701739

Nacheva, 2013, Does BCR/ABL1 positive acute myeloid leukaemia exist?, Br J Haematol, 161, 541, 10.1111/bjh.12301

Cancer Genome Atlas Research Network, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia., N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689

Patel, 2012, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia., N Engl J Med, 366, 1079, 10.1056/NEJMoa1112304

Döhner, 2015, Acute myeloid leukemia., N Engl J Med, 373, 1136, 10.1056/NEJMra1406184

Wouters, 2009, Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome., Blood, 113, 3088, 10.1182/blood-2008-09-179895

Pabst, 2009, Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis., Br J Cancer, 100, 1343, 10.1038/sj.bjc.6604977

Hou, 2009, Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’., Br J Cancer, 101, 738, 10.1038/sj.bjc.6605207

Green, 2010, Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations., J Clin Oncol, 28, 2739, 10.1200/JCO.2009.26.2501

Hollink, 2011, Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia., Haematologica, 96, 384, 10.3324/haematol.2010.031336

Falini, 2010, Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)., Blood, 115, 3776, 10.1182/blood-2009-08-240457

Díaz-Beyá, 2010, The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status., Blood, 116, 6147, 10.1182/blood-2010-09-307314

Bacher, 2012, Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity., Blood, 119, 4719, 10.1182/blood-2011-12-395574

Schnittger, 2011, RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis., Blood, 117, 2348, 10.1182/blood-2009-11-255976

Tang, 2009, AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations., Blood, 114, 5352, 10.1182/blood-2009-05-223784

Mendler, 2012, RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures., J Clin Oncol, 30, 3109, 10.1200/JCO.2011.40.6652

Gaidzik, 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group., J Clin Oncol, 29, 1364, 10.1200/JCO.2010.30.7926

Rozman, 2014, Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1., Ann Hematol, 93, 1695, 10.1007/s00277-014-2100-6

Weinberg, 2009, Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system., Blood, 113, 1906, 10.1182/blood-2008-10-182782

Haferlach, 2009, AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features., Blood, 114, 3024, 10.1182/blood-2009-01-197871

Schlenk, 2013, The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA., Blood, 122, 1576, 10.1182/blood-2013-05-503847

Churpek, 2016, Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia., Cancer, 122, 304, 10.1002/cncr.29615

Walter, 2013, Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients., Blood, 121, 2424, 10.1182/blood-2012-10-462440

Zuo, 2012, Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML., PLoS One, 7, e41485, 10.1371/journal.pone.0041485

Grossmann, 2013, Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics., Leukemia, 27, 1940, 10.1038/leu.2013.144

Porwit, 2011, Acute myeloid leukemia with expanded erythropoiesis., Haematologica, 96, 1241, 10.3324/haematol.2011.050526

Hasserjian, 2010, Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification., Blood, 115, 1985, 10.1182/blood-2009-09-243964

Wang, 2015, Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities., Am J Clin Pathol, 144, 44, 10.1309/AJCPRKYAT6EZQHC7

Yilmaz, 2013, Granulocytic sarcoma: a systematic review., Am J Blood Res, 3, 265

Roy, 2012, Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome., Semin Fetal Neonatal Med, 17, 196, 10.1016/j.siny.2012.02.010

Lange, 1998, Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891., Blood, 91, 608

Yoshida, 2013, The landscape of somatic mutations in Down syndrome-related myeloid disorders., Nat Genet, 45, 1293, 10.1038/ng.2759

Matutes, 2011, Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification., Blood, 117, 3163, 10.1182/blood-2010-10-314682

van den Ancker, 2010, Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification., Leukemia, 24, 1392, 10.1038/leu.2010.119

Kawajiri, 2014, Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status., Int J Hematol, 99, 513, 10.1007/s12185-014-1531-0

Shimizu, 2014, Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era., Eur J Haematol, 93, 297, 10.1111/ejh.12343

Holmfeldt, 2013, The genomic landscape of hypodiploid acute lymphoblastic leukemia., Nat Genet, 45, 242, 10.1038/ng.2532

Mühlbacher, 2014, Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%., Genes Chromosomes Cancer, 53, 524, 10.1002/gcc.22163

Harrison, 2014, An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome., Leukemia, 28, 1015, 10.1038/leu.2013.317

Heerema, 2013, Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group., J Clin Oncol, 31, 3397, 10.1200/JCO.2013.49.1308

Den Boer, 2009, A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study., Lancet Oncol, 10, 125, 10.1016/S1470-2045(08)70339-5

Mullighan, 2009, Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia., N Engl J Med, 360, 470, 10.1056/NEJMoa0808253

Boer, 2015, BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures., Haematologica, 100, e354, 10.3324/haematol.2015.124941

Roberts, 2012, Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia., Cancer Cell, 22, 153, 10.1016/j.ccr.2012.06.005

Harvey, 2010, Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia., Blood, 115, 5312, 10.1182/blood-2009-09-245944

Roberts, 2014, Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia., N Engl J Med, 371, 1005, 10.1056/NEJMoa1403088

Weston, 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J Clin Oncol, 31, e413, 10.1200/JCO.2012.47.6770

Meijerink, 2010, Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia., Best Pract Res Clin Haematol, 23, 307, 10.1016/j.beha.2010.08.002

Ohgami, 2013, Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma., Adv Anat Pathol, 20, 137, 10.1097/PAP.0b013e31828d17ec

Coustan-Smith, 2009, Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia., Lancet Oncol, 10, 147, 10.1016/S1470-2045(08)70314-0

Neumann, 2013, Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations., Blood, 121, 4749, 10.1182/blood-2012-11-465138

Neumann, 2013, FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors., PLoS One, 8, e53190, 10.1371/journal.pone.0053190

Zhang, 2012, The genetic basis of early T-cell precursor acute lymphoblastic leukaemia., Nature, 481, 157, 10.1038/nature10725

Inukai, 2012, Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99-15., Br J Haematol, 156, 358, 10.1111/j.1365-2141.2011.08955.x

Patrick, 2014, Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003., Br J Haematol, 166, 421, 10.1111/bjh.12882

Wood, 2014, T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 [abstract]., Blood, 124, 1, 10.1182/blood.V124.21.1.1